Abstract
Sialylation is a typical final step of glycosylation, which is a prevalent post-translational modification of proteins. Sialoglycans, the products of sialylation, are located on the outmost of cells and participate in pivotal biological processes. They have been identified as glyco-immune checkpoints and are currently under rigorous investigation in the field of tumor research. It is noteworthy that the exploration of sialoglycans in tumor and pregnancy contexts was both initiated in the 1960s. Mechanisms in these two conditions exhibit similarities. Trophoblast infiltration during pregnancy gets controlled, while tumor invasion is uncontrolled. The maternal-fetal immunotolerance balances acceptance of the semiallogeneic fetus and resistance against “non-self” antigen attack simultaneously. Tumors mask themselves with sialoglycans as “don’t eat me” signals to escape immune surveillance. The trophoblastic epithelium is covered with sialoglycans, which have been demonstrated to play an immune regulatory role throughout the entire pregnancy. Immune abnormalities are commonly recognized as an important reason for miscarriages. Therapeutic strategies that desialylation and targeting receptors of sialoglycans have been studied in tumors, while agents that target glyco-immune checkpoints have not been studied in pregnancy. Thus, investigating the roles of sialoglycans in pregnancy and their intersection with tumors may facilitate the development of novel therapies targeting glyco-immune checkpoints for the treatment of pregnancy-related diseases, such as miscarriage and preeclampsia.
1 Introduction
The outermost layer of all cells is decorated with glycocalyx coatings. Sialic acid usually serves as the terminal monosaccharide of the glycocalyx. This outermost location of sialic acid makes it a critical role in mediating cellular connections between cells and the extracellular matrix. Sialic acid-containing glycans (sialoglycans) are engaged in various cellular biological processes () and usually combine with sialic acid-binding immunoglobulin-like lectins (Siglecs). Recent research has elucidated notable roles played by the interactions between sialoglycans and Siglecs in immune responses, thus recognizing them as crucial glyco-immune checkpoints (, ).
The investigation of sialoglycans in tumor immunity is now being conducted widely and rapidly. However, it is noteworthy that around the 1960s, sialic acid was concurrently recognized as a significant determinant in both tumor () and pregnancy (). In these contexts, cells must evade immune surveillance—trophoblasts during gestation and tumor cells during metastatic progression—by manipulating immune checkpoint pathways. The underlying mechanisms of these two conditions are somehow similar. Tumor cells and trophoblastic epithelium are both covered with sialoglycans to escape immune attack (, ). This review aims to investigate the intersection of immune regulatory roles of sialoglycans in pregnancy and tumors, pointing out their potential as therapeutic targets. In order to enhance comprehension of the functions of sialoglycans in pregnancy, we investigated their roles throughout the entirety of the gestational period, as well as their overlap relevance in tumor immunity.
2 The sialoglycan biosynthesis
Sialic acids comprise a collection of more than 50 sugars with nine carbon atoms, which are derived from neuraminic acid or deaminoneuraminic acid (Kdn, Figure 1A). The most prevalent types of sialic acids are N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc), and the former one is the predominant form in humans (Figures 1B, C) (). Neu5Ac is subsequently carried into the nucleus and forms its activated form, cytidine 5’-monophosphate-sialic acid (CMP-Neu5Ac, Figure 1D), by the enzyme CMP-Neu5Ac synthase (CMAS) (, ). The Neu5Ac moiety of CMP-Neu5Ac is transferred to the termini of glycoproteins and glycolipids by sialyltransferases (, ). The process of attaching sialic acids to the terminals of glycocalyx is referred to as sialylation. Enzymes known as β-galactoside α-2,3-sialyltransferases (ST3Gals), β-galactoside α-2,6-sialyltransferases (ST6Gals), and α-N-acetylgalactosaminide α-2,6-sialyltransferases (ST6GalNAcs) catalyze the attachment of sialic acids to galactose (Gal) or N-acetylgalactosamine (GalNAc) through an α-2,3/6-linkage (Figures 1E, F). Alpha-2,8-sialyltransferases (ST8Sias) catalyze the synthesis of polysialic acids (Figure 1G). Sialoglycans are divided into three classes based on the types of above glycosidic bonds: α2,3-sialoglycans, α2,6-sialoglycans, and α2,8-sialoglycans (Figures 1E–G). The enzymatic process of sialylation altered the glycocalyx of cells, affecting cell-cell interactions essential for immune tolerance during pregnancy and tumor immune evasion.
Figure 1
3 Sialoglycan-mediated maternal-fetal interaction
Maintaining the maternal-fetal immunity balance is crucial for a successful pregnancy (). Endogenous sialoglycans, which hinder leukocyte activation via “self-associated molecular patterns” (SAMP) (12) are pivotal for the protection of the semi-allogeneic embryos. The deficiency of sialoglycans due to the genetic removal of CMAS lead to the death of embryos at around 9.5 days after fertilization in mice (13). As shown in Figure 2A, amniotic fluid concentrations of α2,3-sialoglycans and α2,6-sialoglycans are positively related to gestational weeks, suggesting their critical role in maintaining fetal tolerance (14). When complicated with preeclampsia, the concentration of total sialic acids in the saliva of pregnant women exhibited a considerable rise (15); α2,3-sialoglycans concentrations decreased in the syncytiotrophoblast and fetal endothelium of the placental terminal villi (16); levels of α2,6-sialoglycans in the syncytium elevated (17); but the serum levels of sialic acid were not significant changed (18) (Figure 2B). A key pathogenic factor in the development of preeclampsia is the impairment of maternal immune tolerance towards the semiallogeneic fetus (19). It is remains to be revealed if alterations in sialic acid levels in preeclampsia contribute to this immunological imbalance. Moreover, sialoglycans may commence to act even before conception (Figure 2C). The follicular fluid of women who successfully achieved pregnancy through in vitro fertilization may contain higher levels of total sialic acids than those who were unsuccessful (p=0.064; significance was not achieved) (20). Furthermore, sialoglycans are necessary for sperm and embryos to survive in the female reproductive tract (FRT) until delivery (21–24).
Figure 2
3.1 Effects on gamete transit and fertilization
The immune modulation of the FRT commences upon the contact of sperm and seminal fluid to guarantee successful pregnancy (Figure 3A) (21). Sperm-associated sialoglycans impede the leukocytic reaction by interacting with Siglecs on the endometrium, hence facilitating the survival of sperm in the FRT (22). The sialoglycans expressed on surviving sperm engage with Siglecs, leading to the induction of immune suppression within the environment of the oviduct (25). Spermatozoa also impacts fertilization by modulating the immunological response through regulating the chemokine, growth factor, and cytokine expression in the fallopian tube epithelial cells (26). The deficiency of sufficient sialic acid decoration on sperm increases their susceptibility to immune-mediated clearance within the FRT (23). Sperm desialylation is an important step in capacitation, as it enables the unmasking of glycoproteins, which in turn facilitates cell signaling transduction (27). The abnormally sialylated α1-acid glycoprotein has the capacity to induce infertility in males afflicted with a persistent inflammatory disease (28). The negatively charged sialoglycan coat of sperm renders them “invisible” and assists in their maturation and fertilization inside the FRT (29). These findings suggest that sialoglycans play a crucial role in immune modulation before fertilization.
Figure 3
3.2 Impact on the process of implantation
Endometrial receptivity and maternal immune supervision permit the process of allograft fetal extravillous cells infiltrating the maternal endometrium (30). Endometrial decidualization is an essential step in the formation of endometrial receptivity, ensuring the successful implantation of the embryo. Decidualization is the process of transforming the endometrium into decidua during the secretory phase after fertilization (31). The particular N-glycans modifications, including sialylation, of human decidual tissues, were found to have a role in endometrial decidualization (32). The terminal sialyl Lewis X (sLeX) oligosaccharide catalyzed by ST3Gal3 is markedly elevated during the secretory phase and inspires endometrial receptivity (33). Terminal sialylation occurring in the decidua and decidual secretions during early pregnancy is involved in preparing for implantation (34, 35). The glyco-code, which is located on the surface of the blastocyst, contributes a crucial role in determining compatibility with the maternal host and interspecies reproductive isolation (36). The α2,6-sialylation of E-cadherin mediated by ST6Gal1 contributes to embryo adhesion during implantation by modulating uterine lumen closure (24). The interaction between sLeX on the endometrium and the upregulated L-selectin on trophoblasts facilitates the embryo’s adhesion to the endometrial epithelium (37, 38). Adhesion mediated by L-selectin aids cytotrophoblast invasion and migration to the uterus (39). The absence of sialoglycans due to genetic ablation of CMAS in the embryo triggers the activation of complements and leads to an increased infiltration of neutrophils, ultimately resulting in embryonic mortality (13). The outcome of pregnancy is also influenced by maternal NK cells, dendritic cells (DC), macrophages, and T cells in the decidua (31). Sialoglycans play a role in the maternal immune responses that are triggered by these cells against the semiallogeneic antigens of the embryo.
3.3 Immune regulation during pregnancy
The trophoblastic epithelium is covered with a sialic acid-rich coating, which could potentially conceal transplanted antigens (). In a similar manner, tumor cells exploit sialoglycans to mask themselves from immune surveillance (), a mechanism that parallels the maternal-fetal tolerance observed during pregnancy. By antigen masking, sialoglycans impede the direct recognition of immune cells. Moreover, the indirect recognition of sialylated antigens is hindered by their interaction with Siglec-G on DC phagosomes (40). Besides their functions in immune recognition, sialoglycans also exhibit multiple immune regulatory roles (Figure 3). During the process of implantation, leukocytes, comprising around 65%-70% natural killer (NK) cells, 10%-20% major histocompatibility complex class II positive antigen-presenting cells (MHC II+ APC), a few T cells, and almost no B cells, accumulate in the uterus (41, 42). Among the APC population, around 5%-10% of hematopoietic uterine cells are CD11c+ DC (41, 43). During the gestation period of mice, the percentage of CD11c+ DC exhibits an upward trend commencing at E5.5 (embryonic day 0.5, vaginal plug observation defined as gestational day 0.5, E0.5), which corresponds to the completion of implantation. This upward trend persists until E9.5 and remains stable until E17.5 (43). This implies that semiallogeneic embryos initiate the immune responses related to DC and activate particular immunological processes to ensure their survival.
3.3.1 DC-NK cell balance
DC is a potent type of APC that has the ability to activate the adaptive immune response by processing and presenting antigens to naïve T cells. Decidual DC during pregnancy promotes the differentiation of T cells into T regulatory cells (Treg) and decreases the cytotoxicity of NK cells (44). It is well understood that the interactions between NK cells and DC are crucial for maintaining control of innate and adaptive immunity. NK cells, as the most abundant type of leukocytes in the pregnant uterus, do not function as killers, but rather provide the immune regulatory roles (45). Decidual NK cells are reported to release various cytokines and chemokines to regulate cells surrounding them, contributing to placentation, vascular remodeling, trophoblast migration, and immune tolerance (46, 47). Depletion of NK cells has been documented to impede decidual development and result in early pregnancy loss (48, 49). DC expansion enhances the deleterious effects of NK cell ablation by increasing inflammation-related gene expression, immunogenic activation of DC, and imbalanced generation of anti-angiogenic signals (48). Decidual NK cells exhibit high levels of X-C motif chemokine ligand 1 (XCL1), which is recognized by its receptor XCR1 on conventional type 1 dendritic cells (cDC1), thereby recruiting cDC1 (50, 51). During early pregnancy, NK cells recruit and differentiate to decrease the immunogenicity of DCs by secreting IL-10 (Figure 3B) (48). Thus, balanced DC-NK cell interactions are crucial during the process of placentation. Furthermore, the dysregulation of NK cells or DC resulted in changes to the glycophenotype of the implantation sites. The placental labyrinth, which is the location where maternal-fetal exchange occurs, exhibited an alternation of α2,3-linked and α2,6-linked sialic acids after the depletion of NK cells (52). Maintaining a harmonious immune system and proper sialylation patterns are essential for successful implantation and placentation during pregnancy.
Hypersialylation provides a protective mechanism for allogeneic and xenogeneic cells by shielding them from NK immunosurveillance and NK-mediated killing (Figure 3B). One of the explanations is that elevated levels of sialoglycans lead to an increase in Siglecs on NK cells (53). Numerous NK cells emerge at the interface between the mother and fetus during the initial stages of pregnancy but decrease once the placenta established (54). Typically, NK cells are the predominant type of lymphocytes in decidua during normal pregnancy, while they only account for ~10% in the periphery. More than 90% of NK cells are CD56bright in decidua, compared to less than 10% in the periphery (55). Siglec-7 and Siglec-9 are sialoglycan receptors found on human NK cells that suppress the immune response in a manner independent of MHC class I. Siglec-7 is highly abundant on NK cells, while Siglec-9 is absent on CD56bright NK cells but is expressed on 40%–50% of CD56dim NK cells. Siglec-7 is widely detected in CD56bright NK cells from cord blood, but its expression varies significantly in adult peripheral blood. Approximately 10% of CD56bright NK cells derived from cord blood express Siglec-9 after neuraminidase treating. Siglec-7 and Siglec-9 expression levels are elevated in CD56dim NK cells from cord blood when compared to those in the adult periphery. Following neuraminidase treatment, the proportion of CD56dim NK cells expressing Siglec-9 increases from 40% to 60%. CD56dim Siglec-9+ NK cells exhibit reduced cytotoxicity but enhanced chemotactic potential. Thus, it is thought that the presence of Siglec-9 belongs to an initial occurrence during the transition from CD56bright to CD56dim NK cells (56). CD56bright NK cells conduct immunological modulatory functions through the release of different cytokines, whereas CD56dim NK cells exert cytotoxic capabilities (57). Given that a significant proportion of NK cells in the decidua are CD56bright and considering the potential influence of sialoglycans on NK cell differentiation, it may be concluded that NK cells in decidua primarily perform immunological regulatory functions and depend on the presence of sialoglycans.
3.3.2 Decidual T cells regulation and differentiation
Decidual T cells consist of two main subsets: CD4+ T cells, accounting for around 30% to 45%, and CD8+ T cells, comprising around 45% to 75% (58). Decidual CD8+ T cells express elevated amounts of Tim-3 and PD-1, which recognize PD-L1 on extravillous trophoblasts, compared to those in the periphery. This leads to antigen-specific tolerance to trophoblasts (59). Local T regulatory cells (Treg) prevent CD4+ T cells from lysing trophoblast cells (60). During implantation (E3.5), there is a temporary increase in CD4+ CD25+ Foxp3+ Treg cells in uterine draining lymph nodes. They are also found in greater levels in the uteruses of pregnant mice compared to mice in estrous (61). On NK cells and T cells, the sialoglycan receptor Siglec-9 has been found to be expressed along with inhibitory receptors like PD-1, LAG-3, and Tim-3. Their co-expression led to a reduction in the cytotoxicity of these cells (62). Additionally, sialoglycans interact with Siglec-9, which is located in proximity to the TCR-CD3 complex. This interaction inhibits TCR-mediated cell activation by reducing ZAP 70 phosphorylation by recruiting SHP-1 through the immunoreceptor tyrosine-based inhibitory motif (ITIM) phosphorylation (, 63). As above mentioned, Siglecs like Siglec-9 and Siglec-10 within the FRT hinder the leukocytic reaction to facilitate the survival of sperm (22, 64). Glygodelin-A, which is the amniotic glycoform of placental protein 14, acts as a glycoprotein ligand for Siglecs. It promotes the transformation of T cells into Treg rather than effector T cells (Figure 3C) (65, 66). As interactions between Siglecs and sialoglycans act as glyco-immune checkpoints, their roles in maternal-fetal immune tolerance need further investigation. However, the dissimilarities between the Siglec family members in mice and humans restrict their in vivo investigations. Thus, it is necessary to develop particular techniques and methods to address this issue. In recent years, research on sialoglycans in oncology has gained considerable attention, and examining the overlapping roles of sialoglycans in both pregnancy and tumors may foster new research strategies.
4 The overlap relevance in tumor and pregnancy
Tumor progression is partly similar to embryo implantation. The infiltration and invasion of trophoblasts during pregnancy are governed by regulation, whereas that of tumors is characterized by an unrestricted process (67). It is unknown whether these similarities and distinctions between these two conditions contribute to the solution of their complicated issues. Understanding the mechanisms that restrict the invasion of trophoblasts has the potential for developing strategies to halt the pathological proliferation of tumor cells. Similarly, conditions like inadequate remodeling of uterine spiral arteries and recurring implantation failure may be solvable by understanding the mechanisms of tumor progression.
Sialylation, a protein post-translational modification, has been researched in both pregnancy and tumors for decades. As previously discussed, sialoglycans paly crucial roles in maternal-fetal immune regulation throughout pregnancy, contributing to the survival of gametes in FRT and implantation of blastocysts (Figure 4A). Sialic acid is also reported to alter the conformation and flexibility of glycan chains, thus changing the protein functions (68). The presence of sialoglycans on the epidermal growth factor receptor promotes the process of epithelial to mesenchymal (ETM) transition in cancer cells (69) (Figure 4B). Elevated levels of sialoglycans on tumor necrosis factor receptor 1 (TNFR1) and Fas hinder apoptosis signals, allowing cancer cells to escape apoptosis as they move through the blood and lymphatic system, leading to the formation of secondary tumors (70) (Figure 4C). These mechanisms are also being studied in the context of pregnancy (71, 72). Therefore, it is essential to explore the overlap field of sialoglycans in tumor immunity and maternal-fetal immunity (Figure 4). Recent studies have demonstrated that sialoglycan inhibitors, such as anti-Siglec antibodies, are in development for cancer immunotherapy (73, 74). These inhibitors could potentially be repurposed for addressing pregnancy-related immune disorders like preeclampsia.
Figure 4
The presence of Siglec-6 on trophoblast cells and Siglec-5/14 on amniotic epithelium suggests that their interaction with sialylated ligands may play a role in pregnancy (75). Siglec-6, which is uniquely expressed on human placental trophoblast, regulates cell proliferation, invasion, and apoptosis during pregnancy, and its expression in normal placentas drops markedly after eight weeks gestation (76). The dynamic expression of Siglec-6 may indicate that its downregulation serves as a brake on trophoblast invasion. Interestingly, Siglec-6 is also implicated in the progression of certain cancers, such as bladder cancer, where its expression correlates with poor prognosis (77–79). This suggests that Siglec-6 could serve as a shared therapeutic target in both contexts and implies the possibility that physiologic pregnancies hold the secret to preventing cancer invasion.
Within the amniotic epithelium, there is a pair of Siglec receptors, Siglec-5 and Siglec-14. Siglec-5 serves as an inhibiting receptor. Siglec-14 functions as an activating receptor. These receptors are essential for controlling the immune response to invasive infections caused by Group B Streptococci (80). The Siglec-5 molecule also serves as an inhibitory immunological checkpoint in specific tumor cells, and blocking it shows potential in enhancing the T cell immune response against tumors (81). Siglec-14, which shares sequence similarity with Siglec-5, increases the lipopolysaccharide-induced production of TNFα and exhibits distinct immunological properties (82). In the human genome, SIGLEC14 is located near SIGLEC5 and they share a remarkably identical sequence in the coding region at the 5’-end. The fusion gene formed by SIGLEC5 and SIGLEC14 controls the levels of Siglec-5 and Siglec-14 (82). Due to these gene signatures, the extracellular domains of Siglec-5 and Siglec-14 are structurally similar and are capable of recognizing the same ligands. However, these two Siglecs transmit signals through the activation of ITIM and immunoreceptor tyrosine-based activation motif (ITAM), respectively. Co-culture with tamoxifen-treated breast cancer cells induces an immune response of monocytes caused by the overexpression of Siglec-14 rather than Siglec-5. One potential explanation for these changes could be that tamoxifen-induced estrogen-dependent sialoglycan alterations in breast cancer cells (83). These findings imply that tamoxifen has the ability to regulate the immune system and triggers an immunotherapy response through the interaction of sialoglycans and Siglecs. The similar functions of the paired Siglec-5/14 glyco-immune checkpoint in pregnancy and malignancies suggest that the underlying mechanisms of these two conditions are interconnected and complementary.
Likewise, it has been discovered that Siglec-10 interacts with sialoglycans on CD24 in the first-trimester placenta, indicating their involvement in maternal-fetal immune tolerance (84). Siglec-10 possesses two ITIM motifs, which transmit inhibitory intracellular signals (85). The immunosuppression mediated by the interaction of Siglec-10 and CD24, which is known as an innate immune checkpoint, is also observed in tumors. Increased expression of Siglec-10 in kidney renal clear cell carcinoma is associated with a negative outcome. Its expression is potentially orchestrated by transcription factors c-FOS and GATA1 (86). GATA1 expression reaches its highest level during the process of trophoblast attachment to the maternal endometrium. This indicates that GATA1 is involved in the attachment and implantation of the conceptus (87). The investigation of GATA1’s role in regulating Siglec-10 expression during pregnancy has not yet been conducted. Thus, understanding the regulation of Siglecs expression in tumors could offer valuable insights into their expression patterns in pregnancy.
5 Therapeutic potential of glyco-immune checkpoints
The immunological regulating of the maternal-fetal interface serves as a natural example of active immunotolerance, as it maintains a delicate balance between accepting the semiallogeneic fetus and defending against attacks from “non-self” antigens simultaneously (88). The discussion focused on the roles of sialoglycans in pregnancy and tumors as glyco-immune checkpoints. Although tumors during pregnancy are rare (approximately 1 in 1000 pregnancies), there have been reported cases of using immune checkpoint inhibitors (ICIs) (89, 90). ICIs, including monoclonal antibodies that target cytotoxic T-lymphocyte–associated protein 4 (CTLA4), lymphocyte activation gene 3 (LAG3), programmed cell death 1 (PD-1), and its ligand (PD-L1), are commonly used to treat multiple types of tumors (90). ICIs are designed to reestablish the immune response mediated by T cells against cancer cells. Nivolumab and pembrolizumab (anti-PD-1 drugs) are classified as pregnancy category D (positive evidence of risk) by the Food and Drug Administration (FDA), whereas ipilimumab (anti-CTLA-4 antibody) is labeled as pregnancy category C (risk cannot be ruled out). Preclinical studies and some reports show that administration of ICIs for treating tumors during peri-pregnancy period may raise the chances of pregnancy issues, premature birth, low birth weight, and even fetal death (89, 91). Nevertheless, there have been documented clinical instances showing positive outcomes related to pregnancy. Monotherapy with anti-PD-L1 or anti-CTLA4 did not lead to an increase in maternofetal adverse outcomes when compared to other anti-tumor medications. However, the concurrent administration of anti-PD-1 and anti-CTLA4 did lead to (90). Thus, monotherapy and close monitoring of both mothers and fetuses are necessary when administered. The immune-related adverse events here may result from the impaired immune tolerance caused by ICIs.
The establishment of immunological tolerance between the mother and fetus is crucial for the success of pregnancy. Immune system disorders are a typical reason for pregnancy loss. The immune checkpoints have been investigated to be potential biomarkers for recurrent pregnancy loss (92–94). As toxicities of ICIs on fertility, pregnancy, and sexuality have been revealed (95), their potentially therapeutic roles in recurrent spontaneous abortion were not investigated. Recently, agents targeting glyco-immune checkpoints have been studied (96, 97). GLIMMER-01’s phase I findings showed that E-602, a fusion protein made up of modified human sialidase and human IgG1 Fc region, effectively targeted immunosuppressive sialoglycans at the well-tolerated doses (97). Further assessment will be conducted on the monotherapy effectiveness of E-602 in individuals with non-small cell lung cancer and melanoma who are resistant to ICIs. Furthermore, receptors for sialoglycans, including Siglec-6 (77, 98), Siglec-10 (99, 100), and Siglec-15 (101–103), have been identified as targets for tumor therapy in clinical trials. Lirentelimab, an antibody targeting Siglec-8, has been investigated in autoimmune diseases such as chronic urticarial (104). No reports exist on the utilization of ICIs or glyco-immune checkpoint treatment for recurrent pregnancy loss. Further research is necessary to fully elucidate the role of sialoglycans in reproductive immunology. Large-scale clinical trials are required to investigate the safety and efficacy of targeting glyco-immune checkpoints in pregnancy-related complications, and parallel studies in cancer biology could provide valuable insights.
6 Perspectives and conclusions
Sialoglycans are involved in the entire pregnancy period and partially overlap in tumor immunity. Restoring balance to the sialylation process may potentially resolve pregnancy-related disorders like miscarriage and preeclampsia. Given the wide-ranging studies on ICIs, agents that target glyco-immune checkpoints might be a promising therapy for both tumor and pregnancy-related diseases. Interfering with glyco-immune checkpoints to locally regulate immune responses in FRT may serve as a novel therapy with low toxicity. However, further research is required to better comprehend the roles of sialoglycans throughout pregnancy to catch up with the level of knowledge we possess about malignancies. Targeting glyco-immune checkpoints in pregnancy must be approached with caution, as there is a delicate balance between immune tolerance and protection. Disruption of this balance could potentially result in adverse outcomes, such as increased susceptibility to infections or pregnancy complications.
Statements
Author contributions
JH: Conceptualization, Visualization, Writing – original draft. LF: Conceptualization, Visualization, Writing – original draft. JgH: Writing – review & editing. GZ: Supervision, Writing – review & editing. SL: Funding acquisition, Supervision, Writing – review & editing.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was funded by the National Natural Science Foundation of China (grant number 82371864 to SL), the Natural Science Foundation of Henan Province (grant number 232300421121 to SL), and the Major Projects Jointly Constructed by Henan Province and Ministry of Science and Technology (grant number SBGJ202101003 to SL).
Acknowledgments
All authors thank Professor Bingtao Hao (from Department of Immunology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China) for the technical guidance of the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
LiFDingJ. Sialylation is involved in cell fate decision during development, reprogramming and cancer progression. Protein Cell. (2018) 10:550–65. doi: 10.1007/s13238-018-0597-5
2
van de WallSSantegoetsKvan HoutumEBullCAdemaG. Sialoglycans and siglecs can shape the tumor immune microenvironment. Trends Immunol. (2020) 41:274–85. doi: 10.1016/j.it.2020.02.001
3
HuangJHuangJZhangG. Insights into the role of sialylation in cancer metastasis, immunity, and therapeutic opportunity. Cancers. (2022) 14:5840. doi: 10.3390/cancers14235840
4
MacbethRALBekesiJG. Plasma glycoproteins in various disease states including carcinoma. Cancer Res. (1962) 22:1170–6.
5
TachiSTachiCLindnerHR. Ultrastructural features of blastocyst attachment and trophoblastic invasion in the rat. J Reprod Fertil. (1970) 21:37–56. doi: 10.1530/jrf.0.0210037
6
HuangJLiMMeiBLiJZhuYGuoQet al. Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity. J Trans Med. (2022) 20:496. doi: 10.1186/s12967-022-03714-y
7
Munster-KuhnelAKTiralongoJKrappSWeinholdBRitz-SedlacekVJacobUet al. Structure and function of vertebrate CMP-sialic acid synthetases. Glycobiology. (2004) 14:43R–51R. doi: 10.1093/glycob/cwh113
8
MosimannSCGilbertMDombroswkiDToRWakarchukWStrynadkaNC. Structure of a sialic acid-activating synthetase, CMP-acylneuraminate synthetase in the presence and absence of CDP. J Biol Chem. (2001) 276:8190–6. doi: 10.1074/jbc.M007235200
9
MatthewsMMMcArthurJBLiYYuHChenXFisherAJ. Catalytic cycle of neisseria meningitidis CMP-sialic acid synthetase illustrated by high-resolution protein crystallography. Biochemistry. (2020) 59:3157–68. doi: 10.1021/acs.biochem.9b00517
10
ZhaoWChenTLVertelBMColleyKJ. The CMP-sialic acid transporter is localized in the medial-trans Golgi and possesses two specific endoplasmic reticulum export motifs in its carboxyl-terminal cytoplasmic tail. J Biol Chem. (2006) 281:31106–18. doi: 10.1074/jbc.M605564200
11
LinQ-DQiuL-H. Pathogenesis, diagnosis, and treatment of recurrent spontaneous abortion with immune type. Front Med China. (2010) 4:275–9. doi: 10.1007/s11684-010-0101-y
12
VarkiA. Since there are PAMPs and DAMPs, there must be SAMPs? Glycan “self-associated molecular patterns” dampen innate immunity, but pathogens can mimic them. Glycobiology. (2011) 21:1121–4. doi: 10.1093/glycob/cwr087
13
AbelnMAlbersIPeters-BernardUFlachsig-SchulzKKatsEKispertAet al. Sialic acid is a critical fetal defense against maternal complement attack. J Clin Invest. (2019) 129:422–36. doi: 10.1172/JCI99945
14
Orczyk-PawiłowiczMFloriańskiJZalewskiJKatnik-PrastowskaI. Relative amounts of sialic acid and fucose of amniotic fluid glycoconjugates in relation to pregnancy age. Glycoconjugate J. (2005) 22:433–42. doi: 10.1007/s10719-005-4437-5
15
Hernandez-ArteagaACSaucedo GomezACGodinez-HernandezLHernandez-CedilloAHuertaMMYacamanMJet al. Comparative study of sialic acid content in saliva between preeclampsia and normal gestation patients. Placenta. (2022) 130:12–6. doi: 10.1016/j.placenta.2022.10.013
16
ZiganshinaMMKulikovaGVShchegolevAIShmakovRGKanNESukhikhGT. Comparative characteristics of sialoglycans expression disorders in the placental barrier structures in preeclampsia and fetal growth restriction. Bull Exp Biol Med. (2022) 173:270–5. doi: 10.1007/s10517-022-05532-0
17
SukhikhGTZiganshinaMMNizyaevaNVKulikovaGVVolkovaJSYarotskayaELet al. Differences of glycocalyx composition in the structural elements of placenta in preeclampsia. Placenta. (2016) 43:69–76. doi: 10.1016/j.placenta.2016.05.002
18
KaraAEGuneyGTokmakAOzaksitG. The role of inflammatory markers hs-CRP, sialic acid, and IL-6 in the pathogenesis of preeclampsia and intrauterine growth restriction. Eur Cytokine Network. (2019) 30:29–33. doi: 10.1684/ecn.2019.0423
19
LiuDLiQDingHZhaoGWangZCaoCet al. Placenta-derived IL-32β activates neutrophils to promote preeclampsia development. Cell Mol Immunol. (2021) 18:979–91. doi: 10.1038/s41423-021-00636-5
20
Aslan ÇetinBOcalPIrezTUsluEIrmakKKarataşS. The association between follicular fluid sialic acid levels, oocyte quality, and pregnancy rates. Reprod Sci. (2021) 29:633–8. doi: 10.1007/s43032-021-00688-y
21
SchjenkenJESharkeyDJGreenESChanHYMatiasRAMoldenhauerLMet al. Sperm modulate uterine immune parameters relevant to embryo implantation and reproductive success in mice. Commun Biol. (2021) 4:572. doi: 10.1038/s42003-021-02038-9
22
TecleEReynosoHSWangRGagneuxP. The female reproductive tract contains multiple innate sialic acid-binding immunoglobulin-like lectins (Siglecs) that facilitate sperm survival. J Biol Chem. (2019) 294:11910–9. doi: 10.1074/jbc.RA119.008729
23
MaXPanQFengYChoudhuryBPMaQGagneuxPet al. Sialylation facilitates the maturation of mammalian sperm and affects its survival in female uterus. Biol Reprod. (2016) 94:123. doi: 10.1095/biolreprod.115.137810
24
HanKWangFYueYTanXTianMMiaoYet al. Glycomics reveal that ST6GAL1-mediated sialylation regulates uterine lumen closure during implantation. Cell Prolif. (2022) 55:e13169. doi: 10.1111/cpr.13169
25
MolinaLMPepiLEShajahanADoungkamchanKAzadiPMcKimDBet al. Siglecs in the porcine oviduct and sialylated ligands on sperm: roles in the formation of the sperm reservoir. bioRxiv. (2023). doi: 10.1101/2023.03.26.534240
26
MousaviSOMohammadiRAmjadiFZandiehZAghajanpourSAflatoonianKet al. Immunological response of fallopian tube epithelial cells to spermatozoa through modulating cytokines and chemokines. J Reprod Immunol. (2021) 146:103327. doi: 10.1016/j.jri.2021.103327
27
MaFWuDDengLSecrestPZhaoJVarkiNet al. Sialidases on mammalian sperm mediate deciduous sialylation during capacitation. J Biol Chem. (2012) 287:38073–9. doi: 10.1074/jbc.M112.380584
28
KratzEPolandDCvan DijkWKatnik-PrastowskaI. Alterations of branching and differential expression of sialic acid on alpha-1-acid glycoprotein in human seminal plasma. Clinica chimica Acta. (2003) 331:87–95. doi: 10.1016/s0009-8981(03)00084-6
29
YiSFengYWangYMaF. Sialylation: fate decision of mammalian sperm development, fertilization, and male fertilitydagger. Biol Reprod. (2023) 109:137–55. doi: 10.1093/biolre/ioad067
30
MaoJFengYZhuXMaF. The molecular mechanisms of HLA-G regulatory function on immune cells during early pregnancy. Biomolecules. (2023) 13:1213. doi: 10.3390/biom13081213
31
SanguansermsriDPongcharoenS. Pregnancy immunology: decidual immune cells. Asian Pacific J Allergy Immunol. (2008) 26:171–81. doi: 10.1002/crat.200711154
32
ChenSZhangALiNWuHLiYLiuSet al. Elevated high-mannose N-glycans hamper endometrial decidualization. iScience. (2023) 26:108170. doi: 10.1016/j.isci.2023.108170
33
YuMWangHLiuJQinHLiuSYanQ. The sialyltransferase ST3Gal3 facilitates the receptivity of the uterine endometrium in vitro and in vivo. FEBS Lett. (2018) 592:3696–707. doi: 10.1002/1873-3468.13252
34
JonesCJPAplinJDBurtonGJ. First trimester histiotrophe shows altered sialylation compared with secretory phase glycoconjugates in human endometrium. Placenta. (2010) 31:576–80. doi: 10.1016/j.placenta.2010.04.011
35
PassapontiSPavoneVCrestiLIettaF. The expression and role of glycans at the feto-maternal interface in humans. Tissue Cell. (2021) 73:101630. doi: 10.1016/j.tice.2021.101630
36
JonesCJAplinJD. Glycosylation at the fetomaternal interface: does the glycocode play a critical role in implantation? Glycoconjugate J. (2009) 26:359–66. doi: 10.1007/s10719-008-9152-6
37
LiuSZhangYLiuYQinHWangXYanQ. FUT7 antisense sequence inhibits the expression of FUT7/sLeX and adhesion between embryonic and uterine cells. IUBMB Life. (2008) 60:461–6. doi: 10.1002/iub.62
38
ZhangYLiuSLiuYWangZWangXYanQ. Overexpression of fucosyltransferase VII (FUT7) promotes embryo adhesion and implantation. Fertility Sterility. (2009) 91:908–14. doi: 10.1016/j.fertnstert.2007.12.012
39
PrakobpholAGenbacevOGormleyMKapidzicMFisherSJ. A role for the L-selectin adhesion system in mediating cytotrophoblast emigration from the placenta. Dev Biol. (2006) 298:107–17. doi: 10.1016/j.ydbio.2006.06.020
40
DingYGuoZLiuYLiXZhangQXuXet al. The lectin Siglec-G inhibits dendritic cell cross-presentation by impairing MHC class I-peptide complex formation. Nat Immunol. (2016) 17:1167–75. doi: 10.1038/ni.3535
41
PlaksVBirnbergTBerkutzkiTSelaSBenYasharAKalchenkoVet al. Uterine DCs are crucial for decidua formation during embryo implantation in mice. J Clin Invest. (2008) 118:3954–65. doi: 10.1172/jci36682
42
FuMZhangXLiuCLyuJLiuXZhongSet al. Phenotypic and functional alteration of CD45+ immune cells in the decidua of preeclampsia patients analyzed by mass cytometry (CyTOF). Front Immunol. (2023) 13:1047986. doi: 10.3389/fimmu.2022.1047986
43
BloisSMAlba SotoCDTomettenMKlappBFMargniRAArckPC. Lineage, maturity, and phenotype of uterine murine dendritic cells throughout gestation indicate a protective role in maintaining pregnancy1. Biol Reprod. (2004) 70:1018–23. doi: 10.1095/biolreprod.103.022640
44
WeiRLaiNZhaoLZhangZZhuXGuoQet al. Dendritic cells in pregnancy and pregnancy-associated diseases. BioMed Pharmacother. (2021) 133:110921. doi: 10.1016/j.biopha.2020.110921
45
SharmaS. Natural killer cells and regulatory T cells in early pregnancy loss. Int J Dev Biol. (2014) 58:219–29. doi: 10.1387/ijdb.140109ss
46
MahajanDSharmaNRKancharlaSKolliPTripathyASharmaAKet al. Role of natural killer cells during pregnancy and related complications. Biomolecules. (2022) 12:68. doi: 10.3390/biom12010068
47
Moffett-KingA. Natural killer cells and pregnancy. Nature reviews. Immunology. (2002) 2:656–63. doi: 10.1038/nri886
48
WangY-LGonzálezITBarrientosGFreitagNOttoTThijssenVLJLet al. Uterine NK cells are critical in shaping DC immunogenic functions compatible with pregnancy progression. PloS One. (2012) 7. doi: 10.1371/journal.pone.0046755
49
FreitagNZwierMVBarrientosGTirado-GonzálezIConradMLRoseMet al. Influence of relative NK–DC abundance on placentation and its relation to epigenetic programming in the offspring. Cell Death Dis. (2014) 5:e1392–2. doi: 10.1038/cddis.2014.353
50
BottcherJPBonavitaEChakravartyPBleesHCabeza-CabrerizoMSammicheliSet al. NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control. Cell. (2018) 172:1022–37.e1014. doi: 10.1016/j.cell.2018.01.004
51
ZhangXWeiH. Role of decidual natural killer cells in human pregnancy and related pregnancy complications. Front Immunol. (2021) 12:728291. doi: 10.3389/fimmu.2021.728291
52
BorowskiSTirado-GonzalezIFreitagNGarciaMGBarrientosGBloisSM. Altered glycosylation contributes to placental dysfunction upon early disruption of the NK cell-DC dynamics. Front Immunol. (2020) 11:1316. doi: 10.3389/fimmu.2020.01316
53
HudakJECanhamSMBertozziCR. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion. Nat Chem Biol. (2014) 10:69–75. doi: 10.1038/nchembio.1388
54
FuBZhouYNiXTongXXuXDongZet al. Natural killer cells promote fetal development through the secretion of growth-promoting factors. Immunity. (2017) 47:1100–13.e1106. doi: 10.1016/j.immuni.2017.11.018
55
FuBLiXSunRTongXLingBTianZet al. Natural killer cells promote immune tolerance by regulating inflammatory TH17 cells at the human maternal-fetal interface. Proc Natl Acad Sci United States America. (2013) 110:E231–240. doi: 10.1073/pnas.1206322110
56
JandusCBoliganKChijiokeOLiuHDahlhausMDémoulinsTet al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest. (2014) 124:1810–20. doi: 10.1172/jci65899ds1
57
RosenstockPKaufmannT. Sialic acids and their influence on human NK cell function. Cells. (2021) 10:263. doi: 10.3390/cells10020263
58
XuLLiYSangYLiD-JDuM. Crosstalk between trophoblasts and decidual immune cells: the cornerstone of maternal-fetal immunotolerance. Front Immunol. (2021) 12:642392. doi: 10.3389/fimmu.2021.642392
59
WangSCLiYHPiaoHLHongXWZhangDXuYYet al. PD-1 and Tim-3 pathways are associated with regulatory CD8+ T-cell function in decidua and maintenance of normal pregnancy. Cell Death Dis. (2015) 6:e1738. doi: 10.1038/cddis.2015.112
60
YangFZhengQJinL. Dynamic function and composition changes of immune cells during normal and pathological pregnancy at the maternal-fetal interface. Front Immunol. (2019) 10:2317. doi: 10.3389/fimmu.2019.02317
61
NancyPErlebacherA. T cell behavior at the maternal-fetal interface. Int J Dev Biol. (2014) 58:189–98. doi: 10.1387/ijdb.140054ae
62
StanczakMASiddiquiSSTrefnyMPThommenDSBoliganKFvon GuntenSet al. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J Clin Invest. (2018) 128:4912–23. doi: 10.1172/JCI120612
63
van HoutumEJHBüllCCornelissenLAMAdemaGJ. Siglec signaling in the tumor microenvironment. Front Immunol. (2021) 12:790317. doi: 10.3389/fimmu.2021.790317
64
ChenYChenHZhengQ. Siglecs family used by pathogens for immune escape may engaged in immune tolerance in pregnancy. J Reprod Immunol. (2023) 159:104127. doi: 10.1016/j.jri.2023.104127
65
LeeCLLamKKWVijayanMKoistinenHSeppalaMNgEHYet al. The pleiotropic effect of glycodelin-A in early pregnancy. Am J Reprod Immunol. (2016) 75:290–7. doi: 10.1111/aji.12471
66
UnutmazDOchanunaZGeiger-MaorADembinsky-VakninAKarussisDTykocinskiMLet al. Inhibition of effector function but not T cell activation and increase in foxP3 expression in T cells differentiated in the presence of PP14. PloS One. (2010) 5:e12868. doi: 10.1371/journal.pone.0012868
67
FoulkRGenbacevO. Trophoblast implantation versus tumor invasion. In: BarneaERJauniauxESchwartzPE, editors. Cancer and Pregnancy. Springer, London (2001). p. 267–76. doi: 10.1007/978-1-4471-0707-1_21
68
GuillotADauchezMBelloyNJonquetJDucaLRomierBet al. Impact of sialic acids on the molecular dynamic of bi-antennary and tri-antennary glycans. Sci Rep. (2016) 6:35666. doi: 10.1038/srep35666
69
BritainCMBhaleraoNSilvaADChakrabortyABuchsbaumDJCrowleyMRet al. Glycosyltransferase ST6Gal-I promotes the epithelial to mesenchymal transition in pancreatic cancer cells. J Biol Chem. (2021) 296:100034. doi: 10.1074/jbc.RA120.014126
70
ReilyCStewartTJRenfrowMBNovakJ. Glycosylation in health and disease. Nature reviews. Nephrology. (2019) 15:346–66. doi: 10.1038/s41581-019-0129-4
71
ClementeLBirdIM. The epidermal growth factor receptor in healthy pregnancy and preeclampsia. J Mol Endocrinol. (2022) 70:e220105. doi: 10.1530/JME-22-0105
72
Calleja AgiusJShanthiMJauniaux. The role of tumor necrosis factor-receptors in pregnancy with normal and adverse outcome. Int J Interferon Cytokine Mediator Res. (2012) 4:1–15. doi: 10.2147/ijicmr.S22848
73
GianchecchiEArenaAFierabracciA. Sialic acid-siglec axis in human immune regulation, involvement in autoimmunity and cancer and potential therapeutic treatments. Int J Mol Sci. (2021) 22:5774. doi: 10.3390/ijms22115774
74
FengHFengJHanXYingYLouWLiuLet al. The potential of siglecs and sialic acids as biomarkers and therapeutic targets in tumor immunotherapy. Cancers. (2024) 16:289. doi: 10.3390/cancers16020289
75
SchwarzFFongJJVarkiA. Human-Specific Evolutionary Changes in the Biology of Siglecs Vol. 2015. ChakrabartiASuroliaA, editors. Cham: Springer International Publishing (2015) p. 1–16.
76
RumerKKPostMDLariveeRSZinkMUyenishiJKramerAet al. Siglec-6 is expressed in gestational trophoblastic disease and affects proliferation, apoptosis and invasion. Endocr Relat Cancer. (2012) 19:827–40. doi: 10.1530/ERC-11-0379
77
BenmerzougSChevalierMFVerardoMNguyenSCessonVSchneiderAKet al. Siglec-6 as a new potential immune checkpoint for bladder cancer patients. Eur Urol Focus. (2022) 8:748–51. doi: 10.1016/j.euf.2021.06.001
78
SchmidtENLamprinakiDMcCordKAJoeMSojitraMWaldowAet al. Siglec-6 mediates the uptake of extracellular vesicles through a noncanonical glycolipid binding pocket. Nat Commun. (2023) 14:2327. doi: 10.1038/s41467-023-38030-6
79
JiangKYQiLLKangFBWangL. The intriguing roles of Siglec family members in the tumor microenvironment. biomark Res. (2022) 10:22. doi: 10.1186/s40364-022-00369-1
80
AliSRFongJJCarlinAFBuschTDLindenRAngataTet al. Siglec-5 and Siglec-14 are polymorphic paired receptors that modulate neutrophil and amnion signaling responses to group B Streptococcus. J Exp Med. (2014) 211:1231–42. doi: 10.1084/jem.20131853
81
VuchkovskaAGlanvilleDGScurtiGMNishimuraMIWhitePUlijaszATet al. Siglec-5 is an inhibitory immune checkpoint molecule for human T cells. Immunology. (2022) 166:238–48. doi: 10.1111/imm.13470
82
YamanakaMKatoYAngataTNarimatsuH. Deletion polymorphism of SIGLEC14 and its functional implications. Glycobiology. (2009) 19:841–6. doi: 10.1093/glycob/cwp052
83
WielgatPRogowskiKCzarnomysyRWawrusiewicz-KurylonekNNarejkoKBielawskiKet al. Tamoxifen modulates the immune landscape of the tumour microenvironment: the paired siglec-5/14 checkpoint in anti-tumour immunity in an in vitro model of breast cancer. Int J Mol Sci. (2023) 24:5512. doi: 10.3390/ijms24065512
84
SammarMSiwetzMMeiriHFlemingVAltevogtPHuppertzB. Expression of CD24 and Siglec-10 in first trimester placenta: implications for immune tolerance at the fetal-maternal interface. Histochem Cell Biol. (2017) 147:565–74. doi: 10.1007/s00418-016-1531-7
85
ForgioneREDi CarluccioCGuzman-CaldenteyJGaglioneRBattistaFChiodoFet al. Unveiling molecular recognition of sialoglycans by human siglec-10. iScience. (2020) 23:101231. doi: 10.1016/j.isci.2020.101231
86
ZhangCZhangJLiangFGuoHGaoSYangFet al. Innate immune checkpoint Siglec10 in cancers: mining of comprehensive omics data and validation in patient samples. Front Med. (2022) 16:596–609. doi: 10.1007/s11684-021-0868-z
87
BaiHSakuraiTKonnoTIdetaAAoyagiYGodkinJDet al. Expression of GATA1 in the ovine conceptus and endometrium during the peri-attachment period. Mol Reprod Dev. (2012) 79:64–73. doi: 10.1002/mrd.21409
88
MikoEMeggyesMDobaKBarakonyiASzeredayL. Immune checkpoint molecules in reproductive immunology. Front Immunol. (2019) 10:846. doi: 10.3389/fimmu.2019.00846
89
AndrikopoulouAKorakitiAMApostolidouKDimopoulosMAZagouriF. Immune checkpoint inhibitor administration during pregnancy: a case series. ESMO Open. (2021) 6:100262. doi: 10.1016/j.esmoop.2021.100262
90
GougisPHamyASJochumFBihanKCarbonnelMSalemJEet al. Immune checkpoint inhibitor use during pregnancy and outcomes in pregnant individuals and newborns. JAMA network Open. (2024) 7:e245625. doi: 10.1001/jamanetworkopen.2024.5625
91
NosedaRMullerLBedussiFFusaroliMRaschiECeschiA. Immune checkpoint inhibitors and pregnancy: analysis of the VigiBase® spontaneous reporting system. Cancers. (2022) 15:173. doi: 10.3390/cancers15010173
92
ZychMRoszczykADabrowskiFKniotekMZagozdzonR. Soluble forms of immune checkpoints and their ligands as potential biomarkers in the diagnosis of recurrent pregnancy loss-A preliminary study. Int J Mol Sci. (2023) 25:499. doi: 10.3390/ijms25010499
93
MarozioLNuzzoAMGulloEMorettiLCanutoEMTancrediAet al. Immune checkpoints in recurrent pregnancy loss: new insights into a detrimental and elusive disorder. Int J Mol Sci. (2023) 24:13071. doi: 10.3390/ijms241713071
94
ChenZHuangJKwak-KimJWangW. Immune checkpoint inhibitors and reproductive failures. J Reprod Immunol. (2023) 156:103799. doi: 10.1016/j.jri.2023.103799
95
GaruttiMLambertiniMPuglisiF. Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review. ESMO Open. (2021) 6:100276. doi: 10.1016/j.esmoop.2021.100276
96
SharmaMLathersDJohnsonMLukeJPuzanovICurtiBet al. 772 A phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01). J immunotherapy Cancer. (2022) 10:A802–2. doi: 10.1136/jitc-2022-SITC2022.0772
97
LukeJJJohnsonMTolcherAChenCTDaiTCurtiBDet al. Abstract CT034: GLIMMER-01: initial results from a phase 1 dose escalation trial of a first-in-class bi-sialidase (E-602) in solid tumors. Cancer Res. (2023) 83:CT034–4. doi: 10.1158/1538-7445.Am2023-ct034
98
CyrMGMhibikMQiJPengHChangJGaglioneEMet al. Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia. J immunotherapy Cancer. (2022) 10:e004850. doi: 10.1136/jitc-2022-004850
99
van BruggenJACPetersFSMesMRietveldJMCerretaniECretenetGet al. T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells. Blood Adv. (2024) 8:4633–46. doi: 10.1182/bloodadvances.2023011934
100
LvKSunMFangHWangJLinCLiuHet al. Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer. J immunotherapy Cancer. (2023) 11:e007669. doi: 10.1136/jitc-2023-007669
101
WangJSunJLiuLNFliesDBNieXTokiMet al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. (2019) 25:656–66. doi: 10.1038/s41591-019-0374-x
102
HeFWangNLiJHeLYangZLuJet al. High affinity monoclonal antibody targeting Siglec-15 for cancer immunotherapy. J Clin Trans Res. (2021) 7:739–49. doi: 10.18053/jctres.07.202106.010
103
WuQWeiXChenFHuangMZhangSZhuLet al. Aptamer-assisted blockade of the immune suppressor sialic acid-binding immunoglobulin-like lectin-15 for cancer immunotherapy. Angew Chem Int Ed Engl. (2023) 62:e202312609. doi: 10.1002/anie.202312609
104
AltrichterSStaubachPPashaMSinghBChangATBernsteinJAet al. An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria. J Allergy Clin Immunol. (2022) 149:1683–90.e1687. doi: 10.1016/j.jaci.2021.12.772
Summary
Keywords
sialoglycan, glyco-immune checkpoint, pregnancy, maternal-fetal immunity, tumor, immunity
Citation
Huang J, Feng L, Huang J, Zhang G and Liao S (2024) Unveiling sialoglycans’ immune mastery in pregnancy and their intersection with tumor biology. Front. Immunol. 15:1479181. doi: 10.3389/fimmu.2024.1479181
Received
13 August 2024
Accepted
04 December 2024
Published
20 December 2024
Volume
15 - 2024
Edited by
Gabor Laszlo Kovacs, University of Pécs, Hungary
Reviewed by
Panicos Shangaris, King’s College London, United Kingdom
Charlie Fehl, Wayne State University, United States
Updates
Copyright
© 2024 Huang, Feng, Huang, Zhang and Liao.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Guonan Zhang, zhanggn@hotmail.com; Shixiu Liao, ychslshx@zzu.edu.cn
†These authors have contributed equally to this work and share first authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.